Nichi-Iko and Sanofi join forces for biosimilar infliximab in Japan
This article was originally published in Scrip
The large and growing Japanese market for Mitsubishi Tanabe Pharma's (MTP) Remicade (infliximab; licensed from Johnson & Johnson) is continuing to attract biosimilar developers, with Nichi-Iko becoming the latest firm to reveal plans.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.